FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 740 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... May 18, 2021 Want to learn more about Sulforaphanes? December 4, 2020 Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... September 24, 2020 Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... May 8, 2021 Load more HOT NEWS New on NCI’s Websites for July 2021 Cancer in My Community: Providing Free Access to Cancer Care in... FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment EMA Recommends Granting a Marketing Authorisation for Tepotinib
